Global Health Limited — Investor Meet, 04-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: In Q3 FY2025, Medanta reported a consolidated total income of INR 9,595 million, reflecting a 12.3% year-over-year growth. Profit After Tax (PAT) increased by 15.6% to INR 1,429 million, with margins at 14.9% compared to 14.5% in the previous year. EBITDA grew 8.4% to INR 2,538 million, resulting in margins of 26.5%. Notably, average occupancy rates increased to 63.6%, with inpatient volumes up by nearly 12.9%.

2. **Future Outlook and Growth Drivers**: Management is focused on sustainable growth strategies, including new hospital openings, enhancing service capabilities, and investing in innovative medical technology. The upcoming hospital in Noida is anticipated to commence operations in Q1/Q2 FY26, which will further expand capacity.

3. **Order Book and Operational Updates**: Medanta's operational metrics are strong, with international patient revenue growing 14.3% to INR 541 million. New service offerings and expansions across hospitals are in progress, aimed at addressing unmet healthcare needs in key markets.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Analysts sought clarity on growth drivers, particularly in developing hospitals, where revenue rose to INR 3,004 million, signaling effective synergy.

- **Market Position and Competitive Landscape**: Analysts raised concerns about market competition; management responded positively, citing their strong brand recognition and clinical excellence.

- **Operational Challenges or Risks**: Questions about supply chain pressures were addressed; management assured maintaining quality standards through proactive risk management.

- **Capex and Capital Allocation**: Analysts queried future spending; management detailed a planned capex of INR 3,000 crore for expansions over five years.

- **Strategic Priorities and Long-Term Vision**: The focus is on enhancing patient-centric care while expanding operational efficiencies.

5. **Market or Regulatory Updates**: The anticipated merger of the wholly-owned subsidiary MHPL into GHL is expected to streamline operations and reduce costs.

6. **Strategic Focus Areas**: Growth through new specialty services, continuous bed expansions, and technology integration signifies a strategic push to enhance patient care and operational efficiency.

7. **Investor Insight**: Medanta's solid financial performance, growth trajectory, and strategic investments present a compelling case for a ‘buy’ position, especially with the upcoming expansions poised to enhance operational capacity and patient reach.